Drug Mixture May Slow Colon Cancer

Article

NEW YORK - A study recently reported in the New England Journal of Medicine found that combining a new drug with the standard ones could more effectively slow end-stage colorectal cancer, slightly prolonging victims' lives.

The drug irinotecan, also known as Camptosar, is already approved by the Food and Drug Administration (FDA) for treating patients with advanced, Stage IV colorectal cancer after standard drugs fail. Led by Dr. Saltz of Memorial Sloan-Kettering Cancer Center, a three-drug combination of irinotecan, fluorouracil, and leucovorin increased average survival to 15 months from 13 months, and the share of patients whose tumors temporarily shrank went to 50% from 28%.

In the current study, 226 patients received fluorouracil and leucovorin, while 231 patients got periodic shots of those two drugs plus irinotecan. For more information visit www.fda.gov.

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content